Skip to main content

C-RAD and MVZ Prof. Dr. Uhlenbrock und Partner expand collaboration

C-RAD is expanding its collaboration with German customer MVZ Prof. Dr. Uhlenbrock und Partner (MVZ). C-RAD’s products and solutions are already being successfully used at several radiation therapy sites operated by MVZ. In the future, all eight radiation therapy locations will be equipped with C-RAD products and solutions.

The order, which has a value, before taxes, of approximately 8,9 MSEK for C-RAD, includes the complete software suite, including modules for Respiratory Gating, Patient Setup & Positioning, and Motion Monitoring. A service contract is also included. Delivery and installation are expected to commence before the end of the year.

“By using C-RAD’s surface scanning technology, the precise positioning of the patient is significantly facilitated, ensuring stable positioning during daily radiation treatment,” explains Dr. Karin Strehl, specialist in radiation therapy and managing director of radiation therapy at the MVZ. “This enables even more precise positioning and, consequently, more precise radiation treatment.” With the state-of-the-art surface scanning technology, innovative treatments such as respiratory gating or high-precision radiation therapy are becoming part of the standard offering at the MVZ. Therefore, MVZ is pleased to further expand the trusted and successful collaboration with C-RAD. “This underscores our philosophy of advancing progressive solutions for the benefit of our patients and implementing them in practice,” says Dr. Strehl. According to Dr. Strehl, the goal is to regularly modernize the radiation therapy sites with the latest technologies.

“We are thrilled with the successful cooperation with MVZ Prof. Dr. Uhlenbrock und Partner,” says Cecilia de Leeuw, CEO and President of C-RAD AB. “Together, we have achieved remarkable advancements in radiation therapy, ensuring the utmost precision and safety for patients. Our collaboration has streamlined workflows, increased efficiency, and ultimately improved the overall quality of care. We look forward to continuing our partnership and making further strides in advancing cancer treatment.”

Close Menu